Mette J Nielsen Selected Research

farglitazar

1/2022	An MMP-degraded and cross-linked fragment of type III collagen as a non-invasive biomarker of hepatic fibrosis resolution.
1/2019	Assessment of liver fibrosis progression and regression by a serological collagen turnover profile.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mette J Nielsen Research Topics

Disease

15	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 05/2012
12	Fibrosis (Cirrhosis) 01/2022 - 01/2013
6	Liver Diseases (Liver Disease) 01/2022 - 05/2015
4	Non-alcoholic Fatty Liver Disease 01/2022 - 01/2019
3	Fatty Liver 01/2020 - 01/2017
2	End Stage Liver Disease 10/2019 - 01/2018
2	Disease Progression 05/2015 - 02/2015
2	Chronic Hepatitis C 02/2015 - 01/2015
1	Infections 01/2022
1	Binge Drinking 01/2022
1	Obesity 01/2022
1	Inflammation (Inflammations) 12/2021
1	Acute-On-Chronic Liver Failure 12/2021
1	Spontaneous Remission 01/2019
1	Cicatrix (Scar) 01/2019
1	Hepatitis C 01/2019
1	Ascites 01/2018
1	Type 2 Diabetes Mellitus (MODY) 01/2017
1	Insulin Resistance 01/2017
1	Heart Failure 01/2017
1	Weight Gain 01/2017
1	Neoplasms (Cancer) 03/2013
1	Idiopathic Pulmonary Fibrosis 01/2012
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2012
1	Lung Diseases (Lung Disease) 01/2012

Drug/Important Bio-Agent (IBA)

12	CollagenIBA 01/2022 - 01/2012
11	Complement C3 (C3 Complement)IBA 01/2022 - 01/2013
11	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2013
7	Collagen Type III (Type III Collagen)IBA 01/2022 - 01/2012
4	EpitopesIBA 01/2022 - 01/2013
3	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2015
3	Matrix Metalloproteinases (MMPs)IBA 01/2022 - 01/2012
3	ImmunosorbentsIBA 01/2022 - 05/2012
3	EnzymesIBA 01/2022 - 05/2012
2	Peptide Hydrolases (Proteases)FDA Link 01/2022 - 03/2013
2	farglitazarIBA 01/2022 - 01/2019
2	Peptides (Polypeptides)IBA 02/2015 - 05/2012
2	Metalloproteases (Metalloproteinases)IBA 01/2015 - 01/2012
2	Carbon Tetrachloride (Tetrachloromethane)IBA 01/2013 - 05/2012
1	collagen type I trimeric cross-linked peptideIBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	Ethanol (Ethyl Alcohol)IBA 01/2022
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2019
1	Complement C5 (Complement 5)IBA 01/2019
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2019
1	Messenger RNA (mRNA)IBA 01/2018
1	CytokinesIBA 01/2018
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 01/2018
1	Transaminases (Aminotransferases)IBA 01/2018
1	PPAR gammaIBA 01/2017
1	balaglitazoneIBA 01/2017
1	endotrophinIBA 01/2017
1	Pioglitazone (Actos)FDA Link 01/2017
1	Glucose (Dextrose)FDA LinkGeneric 01/2017
1	Insulin (Novolin)FDA Link 01/2017
1	Extracellular Matrix ProteinsIBA 01/2015
1	Antiviral Agents (Antivirals)IBA 01/2015
1	Hydroxyproline (4 Hydroxyproline)IBA 01/2013
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2013
1	salicylhydroxamic acid (SHAM)IBA 05/2012
1	Collagen Type IV (Type IV Collagen)IBA 05/2012
1	N 30IBA 01/2012
1	ThrombospondinsIBA 01/2012
1	DisintegrinsIBA 01/2012

Therapy/Procedure

5	Therapeutics 10/2019 - 01/2013
2	Ligation 01/2018 - 05/2012
1	Bariatric Surgery 01/2022
1	Precision Medicine 01/2019
1	Surgical Portasystemic Shunt (Portosystemic Shunt) 01/2018